Biologic Principles of Immunotherapy for Malignant Gliomas

Seunggu (Jude) Han, Gurvinder Kaur, Isaac Yang, Michael Lim

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The most common primary brain neoplasm is glioblastoma multiforme, which is associated with a dismal prognosis. Despite the recommended treatment regimen of aggressive surgical resection, radiation, and chemotherapy, the median survival remains approximately only 14 months. Due to these minimal improvements in survival of patients despite recent advances in conventional treatments, new modalities such as immunotherapy are being investigated and studied. A hurdle to developing effective immunotherapy is the immunosuppressive characteristics that are the hallmark of malignant gliomas. Effective therapeutic strategies will require overcoming these mechanisms, by augmenting tumor antigen presentation, perhaps in a setting isolated from the tumor microenvironment. The heterogeneity of potential glioma antigens warrants potential targeting of multiple tumor-specific antigens, and discovery and investigation of additional antigens. This article describes the current strategies and principles of immunotherapy for malignant gliomas.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalNeurosurgery clinics of North America
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Glioma
Immunotherapy
Neoplasm Antigens
Antigens
Tumor Microenvironment
Survival
Antigen Presentation
Glioblastoma
Immunosuppressive Agents
Brain Neoplasms
Therapeutics
Radiation
Drug Therapy

Keywords

  • Glioma
  • Immunosuppression
  • Immunotherapy
  • Tumor-specific antigen

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Biologic Principles of Immunotherapy for Malignant Gliomas. / Han, Seunggu (Jude); Kaur, Gurvinder; Yang, Isaac; Lim, Michael.

In: Neurosurgery clinics of North America, Vol. 21, No. 1, 01.01.2010, p. 1-16.

Research output: Contribution to journalReview article

Han, Seunggu (Jude) ; Kaur, Gurvinder ; Yang, Isaac ; Lim, Michael. / Biologic Principles of Immunotherapy for Malignant Gliomas. In: Neurosurgery clinics of North America. 2010 ; Vol. 21, No. 1. pp. 1-16.
@article{bae72b2bfc304609b6b7e7d38981b853,
title = "Biologic Principles of Immunotherapy for Malignant Gliomas",
abstract = "The most common primary brain neoplasm is glioblastoma multiforme, which is associated with a dismal prognosis. Despite the recommended treatment regimen of aggressive surgical resection, radiation, and chemotherapy, the median survival remains approximately only 14 months. Due to these minimal improvements in survival of patients despite recent advances in conventional treatments, new modalities such as immunotherapy are being investigated and studied. A hurdle to developing effective immunotherapy is the immunosuppressive characteristics that are the hallmark of malignant gliomas. Effective therapeutic strategies will require overcoming these mechanisms, by augmenting tumor antigen presentation, perhaps in a setting isolated from the tumor microenvironment. The heterogeneity of potential glioma antigens warrants potential targeting of multiple tumor-specific antigens, and discovery and investigation of additional antigens. This article describes the current strategies and principles of immunotherapy for malignant gliomas.",
keywords = "Glioma, Immunosuppression, Immunotherapy, Tumor-specific antigen",
author = "Han, {Seunggu (Jude)} and Gurvinder Kaur and Isaac Yang and Michael Lim",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.nec.2009.08.001",
language = "English (US)",
volume = "21",
pages = "1--16",
journal = "Neurosurgery Clinics of North America",
issn = "1042-3680",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Biologic Principles of Immunotherapy for Malignant Gliomas

AU - Han, Seunggu (Jude)

AU - Kaur, Gurvinder

AU - Yang, Isaac

AU - Lim, Michael

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The most common primary brain neoplasm is glioblastoma multiforme, which is associated with a dismal prognosis. Despite the recommended treatment regimen of aggressive surgical resection, radiation, and chemotherapy, the median survival remains approximately only 14 months. Due to these minimal improvements in survival of patients despite recent advances in conventional treatments, new modalities such as immunotherapy are being investigated and studied. A hurdle to developing effective immunotherapy is the immunosuppressive characteristics that are the hallmark of malignant gliomas. Effective therapeutic strategies will require overcoming these mechanisms, by augmenting tumor antigen presentation, perhaps in a setting isolated from the tumor microenvironment. The heterogeneity of potential glioma antigens warrants potential targeting of multiple tumor-specific antigens, and discovery and investigation of additional antigens. This article describes the current strategies and principles of immunotherapy for malignant gliomas.

AB - The most common primary brain neoplasm is glioblastoma multiforme, which is associated with a dismal prognosis. Despite the recommended treatment regimen of aggressive surgical resection, radiation, and chemotherapy, the median survival remains approximately only 14 months. Due to these minimal improvements in survival of patients despite recent advances in conventional treatments, new modalities such as immunotherapy are being investigated and studied. A hurdle to developing effective immunotherapy is the immunosuppressive characteristics that are the hallmark of malignant gliomas. Effective therapeutic strategies will require overcoming these mechanisms, by augmenting tumor antigen presentation, perhaps in a setting isolated from the tumor microenvironment. The heterogeneity of potential glioma antigens warrants potential targeting of multiple tumor-specific antigens, and discovery and investigation of additional antigens. This article describes the current strategies and principles of immunotherapy for malignant gliomas.

KW - Glioma

KW - Immunosuppression

KW - Immunotherapy

KW - Tumor-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=70450173710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450173710&partnerID=8YFLogxK

U2 - 10.1016/j.nec.2009.08.001

DO - 10.1016/j.nec.2009.08.001

M3 - Review article

C2 - 19944962

AN - SCOPUS:70450173710

VL - 21

SP - 1

EP - 16

JO - Neurosurgery Clinics of North America

JF - Neurosurgery Clinics of North America

SN - 1042-3680

IS - 1

ER -